FDA Approves Empagliflozin/Linagliptin Combo (Glyxambi) for Type 2

The Boehringer Ingelheim/Eli Lilly and Company combination SGLT2 inhibitor and DPP-4 inhibitor Glyxambi has been approved by the FDA. The empagliflozin/linagliptin combo is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when neither of the individual components are working as effective treatments. See this week’s Item #2 and the Product of the Week.